Nicorandil: A Review of its Pharmacology and Therapeutic Efficacy in Angina Pectoris

Drugs

Volumn 44, Issue 4, 1992, Pages 625-655

  Frampton, James E ^a   Buckley, Micaela M ^a   Fitton, Andrew ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANGINA;

ATENOLOL; DILTIAZEM; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; NICORANDIL; NIFEDIPINE; PROPRANOLOL;

ANGINA PECTORIS; DRUG EFFICACY; DRUG MECHANISM; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; UNSTABLE ANGINA PECTORIS; VARIANT ANGINA PECTORIS;

ANGINA PECTORIS; ANIMAL; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; DRUG TOLERANCE; HEMODYNAMICS; HUMAN; NIACINAMIDE; NICORANDIL; NITRATES; POTASSIUM CHANNELS; VASODILATOR AGENTS;

EID: 0026793237     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199244040-00008     Document Type: Article

References (124)

1. Effects of nicorandil on coronary circulation in patients with ischemic heart disease: comparison with nitroglycerin
2. Effect of nicorandil on coronary spasm
3. Effects of nicorandil on rest and effort angina unresponsive to combination therapy with a calcium antagonist and oral nitrate
4. Efficacy of nicorandil on exercise performance in patients with stable effort angina
5. Hemodynamic effects of nicorandil, isosorbide dinitrate, and dihydralazine in healthy volunteers
6. A controlled single-dose study of the efficacy, dose response and duration of action of nicorandil in angina pectoris
7. K+ channel opening mediates the vasorelaxant effects of nicorandil in the intact vascular system
8. The changing role of the exercise electrocardiogram as a diagnostic and prognostic test for chronic ischaemic heart disease
9. Comparison of the acute hemodynamic and coronary vasodilating effects between nicorandil and glyceryl trinitrate
10. Hemodynamic action of nicorandil in chronic congestive heart failure
11. Acute hemodynamic effects of single-dose nicorandil in coronary artery disease
12. The pharmacology of potassium channels and their therapeutic potential
13. A double-blind comparison of nicorandil and metoprolol in patients with effort stable angina. Abstract
14. Glibenclamide is a competitive antagonist of cromakalim, pinacidil and RP 49356 in guinea-pig pulmonary artery
15. Reduction of size of myocardial infarction with nicorandil, a new antianginal drug, after coronary artery occlusion in dogs
16. Dynamic coronary tone in precipitation, exacerbation and relief of angina pectoris
17. The pharmacology of ATP-sensitive potassium channels in the heart
18. K+ channel openers: moving towards cardioprotection via strengthening of a natural mechanism
19. A review of medical therapy for coronary artery spasm
20. Effects of nicorandil on human cardiac electrophysiological parameters. Abstract
21. Nitrate tolerance: a review of the evidence
22. Pinacidil
23. Pharmacokinetics of nicorandil
24. Beneficial effects of intravenous nicorandil in refractory unstable angina. Abstract
25. Vasodilating actions of 2-nicotinamidoethyl nitrate on porcine and guinea-pig coronary arteries
26. Mechanisms of unstable angina pectoris
27. Usefulness of nicorandil in congestive heart failure
28. Influences of exposure to cigarette smoke on concentration of nicorandil in plasma of rats
29. Effects of nicorandil on coronary circulation and myocardial ischemia
30. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide
31. Nicorandil improves postischemic contractile function independently of direct myocardial effects
32. Methylene blue inhibits coronary arterial relaxation and guanylate cyclase activation by nitroglycerin, sodium nitrite, and amyl nitrite
33. Cromakalim, nicorandil and pinacidil: novel drugs which open potassium channels in smooth muscle
34. Coronary effects of nicorandil in comparison with nitroglycerin in chronic conscious dogs
35. Effects of nicorandil on exercise tolerance in patients with stable effort angina: a double-blind study
36. Nitrate tolerance induced by nicorandil or nitroglycerin is associated with minimal loss of nicorandil vasodilator activity
37. Chronic effects of nicorandil on exercise tolerance in patients with stable effort angina pectoris
38. Effects of nicorandil and verapamil, antianginal agents, on plasma digoxin concentrations in rats and dogs
39. + current by nicorandil (2-nicotinamidoethyl nitrate) in isolated ventricular myocytes
40. Cyclic GMP as possible mediator of coronary arterial relaxation by nicorandil (SG-75)
41. Molecular mechanism of action of nicorandil
42. Nicorandil reduces the basal level of cytosolic free calcium in single guinea-pig ventricular myocytes
43. Bioavailability study of nicorandil before and after meals
44. Comparison of nicorandil and atenolol in stable angina pectoris
45. Spasmolytic action of nicorandil in canine conductive coronary arteries in vivo is not modified by glibenclamide
46. Pharmacokinetics of nicorandil, a new coronary vasodilator, in dogs
47. Comparative pharmacokinetics (PK) and bioavailability of nicorandil (NIC) in subjects with stabilized cirrhosis and matched healthy volunteers
48. The potassium current activated by 2-nicotinamidoethyl nitrate (nicorandil) in single ventricular cells of guinea pigs
49. Beneficial effects of nicorandil on cardiovascular hemodynamics and left ventricular function
50. Evaluation of cross-tolerance between nitroglycerin and nicorandil or isosorbide dinitrates. Abstract
51. Effects of intravenous administration of nicorandil on cardiovascular hemodynamics and left ventricular function
52. Clinical evaluation of intravenous SG-75 in treatment of unstable angina — a multicenter double-blind comparative study with intravenous ISDN
53. Effect of nicorandil on exercise performance in patients with effort angina: a multicenter trial using a treadmill exercise test
54. Assessment of the anti-arrhythmic activity of nicorandil during myocardial ischaemia and reperfusion
55. Comparison of antianginal activity of nicorandil, propranolol and diltiazem with reference to the antianginal mechanism
56. Comparative efficacy of high-dose versus low-dose nicorandil therapy for chronic stable angina pectoris
57. Pharmacology and therapeutic effects of nicorandil
58. Effect of a new coronary vasodilator, nicorandil, on variant angina pectoris
59. Effects of nicorandil on coronary hemodynamics in ischemic heart disease: comparison with nitroglycerin, nifedipine, and propranolol
60. Effectiveness of nicorandil in the preservation of myocardium stressed by transient ischemia and its influence on cardiac metabolism during coronary artery occlusion with subsequent reperfusion: a comparison with isosorbide dinitrate
61. Nicorandil clinical profile. An overview of its haemodynamic properties and therapeutic efficacy
62. Cyclic GMP in nicorandil-induced vasodilatation and tolerance development
63. Is vasospasm related to platelet deposition? Relationship in a porcine preparation of arterial injury in vivo
64. Coronary vasospasm as a possible cause of myocardial infarction
65. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris
66. Elektrophysiologische auswirkungen einer vasodilatation durch nicorandil
67. Haemodynamic effects of intravenous nicorandil: comparison with nitroglycerin. Abstract
68. Effects of glibenclamide and nicorandil on cardiac function during ischaemia and reperfusion in isolated perfused rat hearts
69. Pharmacokinetics of nicorandil in patients with normal and impaired renal function
70. 2+)-ATPase activity of vascular smooth muscle cells
71. Effects of intravenous injection of nicorandil on systemic and coronary hemodynamics in patients with old myocardial infarction (OMI) — a comparative study with nifedipine and ISDN. Abstract
72. Development of tolerance and a new coronary vasodilator, N-(2-hydroxyethyl)nicotinamide nitrate (SG-75): a comparison with nitroglycerin
73. + channel openers, cromakalim, pinacidil and nicorandil on allergic reaction and experimental asthma
74. Influence of nicorandil, an antianginal agent, on the therapeutic and toxic cardiovascular actions of ouabain in the anaesthetised dog
75. + channel in guinea-pig ventricular myocytes
76. ATP-regulated potassium channels in cardiac muscle
77. Different effects of various vasodilators on autoregulation of renal blood flow in anesthetized dogs
78. The effects of nicorandil on hemodynamics and myocardial perfusion in coronary artery disease. Abstract
79. Effects of nicorandil on hemodynamics in congestive heart failure. Abstract
80. Salutary action of nicorandil, a new antianginal drug, on myocardial metabolism during ischemia and on postischemic function in a canine preparation of brief, repetitive coronary artery occlusions: comparison with isosorbide dinitrate
81. +channel activators, RP 52891, cromakalim and diazoxide, on the plasma insulin level, plasma renin activity and blood pressure in rats
82. Hemodynamic responses to intravenous nicorandil in congestive heart failure (CHF)
83. + channel openers, a class of drugs with vasorelaxant and cardioprotective properties
84. Comparative efficacy and safety of nitroglycerin, verapamil and nicorandil during coronary angioplasty
85. Nicorandil: animal pharmacology
86. Hypotensive effect and biotransformation of nicorandil, a new antianginal agent, administered to rats by different routes: comparison with nitroglycerin and isosorbide dinitrate
87. Nitrate tolerance: comparison of nicorandil, isosorbide dinitrate and nitroglycerin in anaesthetised dogs
88. Pharmacodynamic and metabolism studies on a new coronary vasodilator, N-(2-hydroxyethyl)nicotinamide nitrate (SG-75)
89. Differential antagonism by glibenclamide of the relaxant effects of cromakalim, pinacidil and nicorandil on canine large coronary arteries
90. +channel in insulin-secreting cells
91. Effects of nicorandil on left ventricular hemodynamics and volume at rest and during exercise-induced angina pectoris
92. Repeat treadmill exercise testing: variability of results in patients with angina pectoris
93. Coronary vasodilatory action after a single dose of nicorandil
94. Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates: an overview
95. Nicorandil as a hybrid between nitrates and potassium channel activators
96. Pharmacological profile of a new coronary vasodilator drug, 2-nicotinamidoethyl nitrate (SG-75)
97. + channel by nicorandil in guinea-pig cardiac cell membrane
98. Cardioprotective effect of nicorandil during percutaneous transluminal coronary angioplasty
99. Effectiveness of nicorandil (SG-75), a new long-acting drug with nitroglycerin effects, in patients with coronary artery disease: improved left ventricular function and regional wall motion and abolition of pacing-induced angina
100. Clinical electrophysiological effects of nicorandil on the conduction system in humans
101. Nicorandil does not develop tolerance in patients with congestive heart failure. Abstract
102. Mechanism of nicorandil intolerance in patients with heart failure. Abstract
103. + channel opener, on left ventricular function in coronary artery disease: comparison with nitroglycerin and nifedipine
104. Cytoplasmic calcium and the relaxation of canine coronary arterial smooth muscle produced by cromakalim, pinacidil and nicorandil
105. Effects of a new vasodilator, nicorandil, on exercise-induced impairment of left ventricular function in patients with old myocardial infarction
106. Nicorandil in the treatment of angina pectoris
107. Nicorandil increases coronary blood flow predominantly by K-channel opening mechanism